TY - JOUR
AU - Gasbarrini, A.
AB - Background: Moxifloxacin is a broad spectrum fluoroquinolone with single daily administration, currently used, above all, for respiratory tract infections. Aim: To compare the efficacy of different 1‐week moxifloxacin‐based Helicobacter pylori eradication regimens. Methods: One hundred and twenty H. pylori‐positive subjects were randomized to receive moxifloxacin (400 mg/day), moxifloxacin (400 mg/day) and lansoprazole (30 mg/day) or moxifloxacin (400 mg/day), lansoprazole (30 mg/day) and clarithromycin (500 mg b.d.). H. pylori status was reassessed 6 weeks after the end of therapy, and both intention‐to‐treat and per protocol analyses were performed. Results: One hundred and nineteen of the 120 patients completed the study. H. pylori eradication was achieved in 22.5% of patients treated with moxifloxacin, in 33.3% of subjects treated with moxifloxacin and lansoprazole and in 90% of patients treated with moxifloxacin, clarithromycin and lansoprazole. Conclusions: Mono and dual moxifloxacin‐based therapies are not acceptable for H. pylori eradication; conversely, moxifloxacin‐based triple therapy may be considered as a new, effective, first‐line therapy option.
TI - Mono, dual and triple moxifloxacin‐based therapies for Helicobacter pylori eradication
JF - Alimentary Pharmacology & Therapeutics
DO - 10.1046/j.1365-2036.2002.01165.x
DA - 2002-03-01
UR - https://www.deepdyve.com/lp/wiley/mono-dual-and-triple-moxifloxacin-based-therapies-for-helicobacter-qKiSTLGvW0
SP - 527
VL - 16
IS - 3
DP - DeepDyve
ER -